Open Access

Nocturnal CPAP improves walking capacity in COPD patients with obstructive sleep apnoea

  • Tsai-Yu Wang1,
  • Yu-Lun Lo1,
  • Kang-Yun Lee1,
  • Wen-Te Liu2, 3,
  • Shu-Min Lin1,
  • Ting-Yu Lin1,
  • Yung-Lun Ni4,
  • Chao-Yung Wang5,
  • Shu-Chuan Ho1, 3 and
  • Han-Pin Kuo1Email author
Contributed equally
Respiratory Research201314:66

https://doi.org/10.1186/1465-9921-14-66

Received: 11 February 2013

Accepted: 17 June 2013

Published: 19 June 2013

Abstract

Background

Exercise limitation is an important issue in patients with chronic obstructive pulmonary disease (COPD), and it often co-exists with obstructive sleep apnoea (overlap syndrome). This study examined the effects of nocturnal continuous positive airway pressure (CPAP) treatment on walking capacity in COPD patients with or without obstructive sleep apnoea.

Methods

Forty-four stable moderate-to-severe COPD patients were recruited and completed this study. They all underwent polysomnography, CPAP titration, accommodation, and treatment with adequate pressure. The incremental shuttle walking test was used to measure walking capacity at baseline and after two nights of CPAP treatment. Urinary catecholamine and heart rate variability were measured before and after CPAP treatment.

Results

After two nights of CPAP treatment, the apnoea-hypopnoea index and oxygen desaturation index significantly improved in both overlap syndrome and COPD patients, however these changes were significantly greater in the overlap syndrome than in the COPD group. Sleep architecture and autonomic dysfunction significantly improved in the overlap syndrome group but not in the COPD group. CPAP treatment was associated with an increased walking capacity from baseline from 226.4 ± 95.3 m to 288.6 ± 94.6 m (P < 0.05), and decreased urinary catecholamine levels, pre-exercise heart rate, oxygenation, and Borg scale in the overlap syndrome group. An improvement in the apnoea-hypopnoea index was an independent factor associated with the increase in walking distance (r = 0.564).

Conclusion

Nocturnal CPAP may improve walking capacity in COPD patients with overlap syndrome.

Trial registration

NCT00914264

Keywords

Chronic obstructive pulmonary disease Obstructive sleep apnoea Walking capacity Autonomic dysfunction Continuous positive airway pressure

Introduction

Mortality due to chronic obstructive pulmonary disease (COPD) is increasing, and COPD is a serious health burden worldwide. The characteristic physiological impairments are airflow limitation, air-trapping, hyper-inflation, dyspnoea, and exercise limitation [1]. Patients with COPD and exercise limitation will adopt a more sedentary lifestyle and give up the more strenuous physical activities [2, 3], which eventually leads to de-conditioning and ultimately further exercise limitation [4]. Moreover, exercise limitation is associated with morbidity and mortality [5, 6]. As such, finding ways to break this vicious cycle of exercise limitation is an important issue in COPD. Exercise limitation is influenced by age, body weight, dyspnoea sensation, pulmonary function, skeletal muscles, hypoxemia, cardio-vascular function, autonomic dysfunction, and emotion [7]. Nocturnal intermittent hypoxemia and sleep fragmentation have also been shown to be associated with impaired walking performance in older men [8]. In COPD patients, it has been suggested that hypoxemia during exercise limits walking performance, but that this is improved by oxygen supply during exercise [9, 10]. However, whether nocturnal intermittent hypoxemia affects walking performance remains unclear.

Obstructive sleep apnoea (OSA) is characterized by recurrent pharyngeal collapse with intermittent hypoxemia during sleep and subsequent repetitive arousal to maintain ventilation. Concomitant COPD and OSA, termed the overlap syndrome, is not rare and affects at least 1% of the general population [1113]. Nocturnal continuous positive airway pressure (CPAP) via a pneumatic splint is effective in maintaining upper airway patency, and is standard treatment for OSA [14]. In addition, it can reverse sleep fragmentation, nocturnal intermittent hypoxemia and autonomic dysfunction. Therefore, it is reasonable to assume that reversing intermittent hypoxemia, sleep fragmentation and autonomic dysfunction will improve walking performance in overlap syndrome patients. The aim of this study was to clarify whether walking performance significantly increases in COPD patients with OSA after nocturnal CPAP treatment.

Materials and methods

This prospective, controlled, observational study was performed at one sleep centre of a tertiary hospital (Chang Gung Memorial Hospital) from January 2009 to May 2012. The local Ethics Committee of Chang Gung Memorial Hospital approved the research protocol (NCT00914264) and each patient provided written informed consent.

Subjects

Outpatients with stable COPD were enrolled from the thorax department of Chang Gung Memorial Hospital. The inclusion criteria were FEV1/FVC less than 70%, a smoking history of at least 10 pack-years, and snoring (≥ 3 nights/week). The exclusion criteria were an age younger than 40 years, bronchiectasis, acute exacerbation within 2 months of the study, renal insufficiency, heart failure, neuromuscular disease, mood disorder, malignancy, claustrophobia, chronic respiratory failure (PaO2 < 60 mmHg or PaCO2 > 50 mmHg in room air), or sleep disorders other than OSA.

Study design

This study investigated the effects of two nights of CPAP treatment on the walking capacity of COPD patients with or without OSA. All patients underwent polysomnography on the first night to identify those with OSA. The incremental shuttle walking test (ISWT) was then performed by all of the study patients on the morning of the second day. The patients also underwent CPAP accommodation and titration according to published guidelines to determine the optimal pressure on the second night [15]. On the third night, the optimal pressure was applied to all of the study patients. The ISWT was performed again on the morning of the fourth day. Urine was collected from 10 pm to 7 am on the first and third nights and sent to the central lab for catecholamine analysis. The assistants and technicians who helped with the ISWT and urine analysis were blinded to the severity of OSA. In addition, the patients were not aware of the severity of OSA. All patients received regular rehabilitation programs, and medical care did not change during the study period.

Polysomnography and CPAP titration

Polysomnography (Alice 5, Respironics) was performed on all patients using standard techniques on the first night. Sleep stages and arousals were scored according to the AASM criteria [16]. Respiratory efforts were measured by respiratory plethysmography, and arterial oxygen saturation was measured by pulse oximetry. Established criteria were used to score respiratory events such as hypopnoea, obstructive apnoea, central apnoea, mixed type apnoea, and Cheyne-Stokes respiration [17]. Apnoea was defined as oronasal flow cessation for more than 10 seconds. Hypopnoea was defined as a 50% reduction in oronasal flow for more than 10 seconds or a 30% reduction followed by arousal or more than 3% decrease in SaO2. Based on the polysomnography results, OSA was defined as an apnoea/hypopnoea index (AHI) > 15 per hour, of which ≥ 50% were obstructive. CPAP titration to determine optimal pressure was performed according to standard guidelines [15].

Heart rate variability and data analysis

After waking, all patients were requested to breathe regularly and as smoothly as possible in a quiet environment. CPAP was removed as soon as the patients awoke in the morning. The first available 5-minute RR data after waking without CPAP was identified for each patient on the second and fourth mornings. The details of the measurement of heart rate variability are described in the online supplement.

Urinary catecholamine levels

Patients were requested to collect urine samples from 10:00 pm to 7:00 am. The urine samples were collected in polyethylene containers, acidified with 6 M HCl as a preservative, and stored at 2-8°C until analysis [18, 19]. Urinary levels of catecholamines were measured by high performance liquid chromatography with a Bio-Rad kit at the central laboratory of our hospital.

Incremental shuttle walking test

The ISWT was used to determine maximal walking capacity [20, 21]. All of the patients performed the ISWT at least once before the study. The test was then repeated on the mornings of the second (baseline) and fourth (after nocturnal CPAP treatment) days. The details of the ISWT are described in the online supplement and a previous study [20].

Statistical analysis

Data were expressed as group percentages (categorical variables) or mean ± standard deviation (SD, continuous variables), and compared between pre- and post-CPAP treatment. Categorical variables were compared by the chi-square or Fisher’s exact test where appropriate. The paired t-test was used to compare continuous variables with normal distribution and paired samples. The Wilcoxon matched signed rank test was used for paired samples not distributed normally (all P < 0.05). The Pearson product correlation coefficient was used to examine correlations between variables and the change in walking distance. Multivariate linear regression analysis was used to determine independent factors affecting the change in walking distance. All analyses were performed using the SPSS software package version 13.0 and Prism 5, and a P value of less than 0.05 was considered to indicate statistical significance.

Results

Subject characteristics and polysomnography results

A flow chart of the study design is shown in Figure 1, and the patients’ characteristics at baseline are shown in Table 1. Forty-four COPD patients were recruited and completed this study. There was a higher percentage of overlap syndrome patients (50%) in this study than in previous reports, which may be explained by the inclusion criterion of habitual snoring [22]. There were no significant differences in age, gender, body mass index, pulmonary function, arterial blood gas, medications and comorbidities between the groups, however the overlap syndrome patients seemed to be sleepier and have poorer sleep quality than the COPD patients. The mean body mass index in the overlap syndrome group was 24.9 ± 3.5 kg/m2, which is much lower than that reported in Caucasians, but compatible with Asian OSA patients [23]. There were no significant differences in baseline total sleep time, sleep efficiency, mean oxygen saturation during sleep or sleep architecture between the groups (Table 2). The mean AHI in the overlap syndrome group was 39.2 ± 16.5/h of sleep, indicating that most of the patients had severe OSA (Table 2). CPAP treatment did not affect sleep efficiency or total sleep time in either group, however it significantly decreased AHI and oxygen desaturation index (ODI) in both groups. This treatment effect was significantly greater in the overlap syndrome group than in the COPD group. CPAP treatment also significantly increased the average and minimal SaO2 in both groups (Table 2). CPAP treatment improved sleep architecture in the patients with overlap syndrome, but not in those with COPD, by decreasing the proportion of stage 1 sleep (from baseline 23.0 ± 14.0% to 15.4 ± 8.9%, P < 0.05) and increasing slow wave sleep (from baseline 2.3 ± 3.9% to 5.2 ± 6.1%, P < 0.05) as well as REM stage sleep (from baseline 8.5 ± 7.1% to 16.4 ± 10.3%, P < 0.05) (Table 2).
Figure 1

Flow chart of the study design.

Table 1

Patient characteristics

 

Overlap syndrome n = 22

COPD n = 22

p-value

Age

70.0 ± 8.3

71.7 ± 8.5

0.495

Male, n (%)

21 (96.7)

22 (100)

0.999

BMI

24.9 ± 3.5

22.9 ± 3.0

0.054

Smoking, pack-years

52.3 ± 21.5

50.8 ± 26.4

0.837

ESS

12.7 ± 4.5

8.3 ± 3.5

0.004

PSQ

11.8 ± 4.0

7.5 ± 3.7

0.001

Emphysema predominant, n (%)

5 (22.7)

14 (63.6)

0.014

Pulmonary function test

   

FEV1/FVC

57.5 ± 12.7

54.5 ± 9.6

0.197

FEV1 (L)

1.09 ± 0.51

0.95 ± 0.45

0.227

FEV1 (% predicted)

52.7 ± 28.6

45.1 ± 19.2

0.431

FVC (L)

1.87 ± 0.69

1.70 ± 0.60

0.348

FVC (% predicted)

63.3 ± 25.1

57.2 ± 21.7

0.378

Arterial blood gas

   

pH

7.4 ± 0.0

7.4 ± 0.0

0.672

PaCO2 (mm Hg)

41.8 ± 3.8

40.6 ± 3.8

0.354

PaO2 (mmHg)

77.5 ± 11.9

79.2 ± 9.0

0.581

Medication

   

LABA + ICS, n (%)

20 (90.9)

19 (86.4)

0.565

LAMA, n (%)

18 (81.8)

17 (77.3)

0.907

Theophyllines, n (%)

6 (27.3)

2 (9.1)

0.375

Comorbidities

   

DM, n (%)

0 (0)

1 (4.5)

-

HTN, n (%)

10 (45.4)

8 (36.4)

0.348

CAD, n (%)

1 (4.5)

1 (4.5)

0.823

PAOD, n (%)

0 (0)

0 (0)

-

Data are presented as mean ± SD, or number (percentage).

BMI body mass index, ESS Epworth sleepiness scale, PSQ Pittsburg sleep quality, FEV1 forced expiratory volume in one second, FVC forced volume capacity, ICS inhaled corticosteroids, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, DM diabetes mellitus, HTN hypertension, CAD coronary artery disease, PAOD peripheral arterial occlusion disease.

Table 2

Polysomnographic report: patients with and without CPAP treatment

 

Overlap syndrome

 

COPD

  

n = 22

 

n = 22

 

Baseline

With CPAP

P

Baseline

With CPAP

P

P

Total sleep time (minutes)

294.3 ± 80.5

290.1 ± 94.9

0.758

287.8 ± 77.9

273.2 ± 71.7

0.408

0.760

Sleep efficiency (%)

67.2 ± 12.8

68.6 ± 14.3

0.833

66.3 ± 14.2

65.2 ± 12.9

0.650

0.699

AHI event. h-1

39.2 ± 16.5

4.6 ± 2.9

0.001

7.5 ± 4.1*

1.6 ± 1.4

0.001

0.001

ODI event. h-1

20.4 ± 16.2

3.1 ± 2.9

0.001

3.1 ± 2.2*

0.9 ± 1.1

0.001

0.001

Average SaO2%

93.3 ± 2.2

94.5 ± 1.7

0.011

93.8 ± 2.0

94.9 ± 2.1

0.001

0.866

Lowest SaO2%

80.3 ± 8.8

89.3 ± 3.9

0.001

87.0 ± 4.6*

90.2 ± 4.3

0.005

0.089

Wake%

26.6 ± 10.3

21.8 ± 13.7

0.211

25.5 ± 14.2

26.9 ± 12.7

0.578

0.124

N1%

23.0 ± 14.0

15.4 ± 8.9

0.010

20.3 ± 14.1

16.5 ± 8.7

0.079

0.296

N2%

39.5 ± 12.6

41.2 ± 14.9

0.700

34.0 ± 11.8

33.2 ± 11.6

0.941

0.751

N3%

2.3 ± 3.9

5.2 ± 6.1

0.001

7.5 ± 9.4

9.2 ± 11.4

0.235

0.191

REM%

8.5 ± 7.1

16.4 ± 10.3

0.004

12.2 ± 7.7

13.9 ± 7.5

0.144

0.026

CPAP pressure (cm H2O)

 

6.8 ± 1.8

  

4.9 ± 0.9*

  

*P < 0.05; when compared with baseline overlap syndrome group.

P values represent comparisons between baseline and with CPAP in each corresponding group.

P values represent comparisons with regards to the changes with CPAP treatment between overlap syndrome and COPD in each corresponding group.

AHI apnoea/hypopnea index, ODI oxygen desaturation index, SWS slow wave sleep, REM rapid eye movement, CPAP continuous positive airway pressure.

Heart rate variability and urinary catecholamine levels

Four patients (18.2%) in the overlap syndrome group and two patients (9.1%) in the COPD group were excluded from heart rate variability analysis due to arrhythmias. The patients with overlap syndrome (n = 18) had significantly higher baseline LF (46.6 ± 16.1 nu, P < 0.05), LF/HF (1.8 ± 1.2, P < 0.05) and lower HF (32.2 ± 12.0 nu, P < 0.05) on awakening from sleep than the patients with COPD (31.8 ± 10.8 nu, 0.9 ± 0.6 and 41.9 ± 12.1 nu, respectively, n = 20) (Table 3). To further investigate the decrease in sympathetic activity after CPAP treatment in the overlap syndrome patients, urine catecholamine measurements were added into the protocol of this study. Urine samples were collected from all of the study patients except for four patients with overlap syndrome who refused the urine study. The results revealed higher levels of norepinephrine and epinephrine in the patients with overlap syndrome (17.0 ± 8.4 μg and 2.4 ± 0.9 μg, respectively, n = 12) than those in the COPD patients (11.1 ± 5.3 μg and 1.5 ± 0.6 μg, respectively, P < 0.05, n = 12) (Table 3). After CPAP treatment, LF (31.3 ± 16.7 nu, P < 0.05, n = 18), LF/HF (0.9 ± 0.7, P < 0.05, n = 18), and urinary levels of norepinephrine and epinephrine (10.4 ± 6.4 μg and 1.4 ± 0.7 μg, respectively, P < 0.05, n = 12) significantly decreased in the overlap syndrome group, but not in the COPD group. HF also significantly increased after CPAP treatment in the overlap syndrome group (43.1 ± 19.1 nu, P < 0.05, n = 18), but not in the COPD group (Table 3).
Table 3

Heart rate variability and urine catecholamine: patients with and without CPAP treatment

Heart rate variability

Overlap syndrome n = 18#

 

COPD

 

n = 20@

 

Baseline

With CPAP

p

Baseline

With CPAP

p

LF (nu)

46.6 ± 16.1

31.3 ± 16.7

0.001

31.8 ± 10.8*

28.7 ± 20.4

0.401

HF (nu)

32.2 ± 12.0

43.1 ± 19.1

0.029

41.9 ± 12.1*

43.6 ± 19.3

0.287

LF/HF

1.8 ± 1.2

0.9 ± 0.7

0.003

0.9 ± 0.6*

1.2 ± 1.9

0.514

Urine catecholamines

Overlap syndrome n = 12 $

 

COPD

 

n = 12 $

 

Baseline

With CPAP

 

Baseline

With CPAP

 

Norepinephrine, ug

17.0 ± 8.4

10.4 ± 6.4

0.003

11.1 ± 5.3*

11.9 ± 7.5

0.485

Epinephrine, ug

2.4 ± 0.9

1.4 ± 0.7

0.025

1.5 ± 0.6*

1.8 ± 0.8

0.374

*P < 0.05; when compared with baseline overlap syndrome group.

P values represent comparisons between before and after CPAP in each corresponding group.

LF low frequency, HF high frequency nu normalized unit.

Incremental shuttle walking test

There were no significant differences in baseline walking distance, pre-exercise or post-exercise Borg scale, oxygen saturation, heart rate or inspiratory capacity (IC) between the overlap syndrome and COPD groups (Table 4). For patients with overlap syndrome, CPAP treatment significantly increased walking distance (from baseline from 226.4 ± 95.3 m to 288.6 ± 94.6 m, P < 0.05), and pre-exercise oxygenation (from baseline 94.5 ± 2.2% to 95.5 ± 1.9%, P < 0.05), and significantly decreased pre-exercise Borg scale (from 1.5 ± 1.5 to 0.8 ± 1.1, P < 0.05) and heart rate (from 94.3 ± 17.7/min to 87.3 ± 15.8/min, P < 0.05) (Table 4). CPAP treatment did not significantly affect pre-exercise IC or delta-IC in the patients with overlap syndrome (Table 4). In the patients with COPD, CPAP treatment also improved walking distance, however, the increase in walking distance (delta-distance) in the overlap syndrome group (62.3 ± 24.9 m) was significantly greater than that in the COPD group (15.1 ± 33.6 m). In addition, CPAP treatment did not improve pre-exercise Borg scale, heart rate, or IC in the COPD group (Table 4).
Table 4

Incremental shuttle walking test: before and after CPAP treatment

Variable

Overlap syndrome

COPD

 

n = 22

n = 22

Before

After

p

Before

After

p

P

 

CPAP

CPAP

 

CPAP

CPAP

  

Distance (metre)

226.4 ± 95.3

288.6 ± 94.6

0.001

257.5 ± 89.1

272.5 ± 98.4

0.035

0.001

Borg scale (pre-exercise)

1.5 ± 1.5

0.8 ± 1.1

0.040

1.4 ± 1.3

0.7 ± 1.1

0.064

0.832

Borg scale (post-exercise)

4.9 ± 0.9

4.8 ± 1.1

0.851

5.0 ± 1.1

4.7 ± 1.2

0.450

0.596

SaO2 (pre-exercise)

94.5 ± 2.2

95.5 ± 1.9

0.014

94.6 ± 2.7

95.3 ± 2.2

0.046

0.351

SaO2 (post-exercise)

88.8 ± 4.4

87.8 ± 6.3

0.827

85.1 ± 6.0

84.6 ± 5.7

0.717

0.972

Heart rate (pre-exercise)

94.3 ± 17.7

87.3 ± 15.8

0.009

93.2 ± 15.6

93.4 ± 16.1

0.999

0.026

Heart rate (post-exercise)

136.3 ± 24.2

125.0 ± 22.8

0.018

125.3 ± 29.3

134.8 ± 29.6

0.135

0.010

Delta-IC (L)

−0.04 ± 0.23

−0.08 ± 0.17

0.489

−0.13 ± 0.21

−0.12 ± 0.24

0.979

0.548

IC pre-exercise (L)

1.37 ± 0.48

1.44 ± 0.48

0.184

1.34 ± 0.42

1.32 ± 0.42

0.687

0.171

IC post-exercise (L)

1.33 ± 0.48

1.36 ± 0.46

0.586

1.21 ± 0.42

1.20 ± 0.49

0.672

0.225

P values represent comparisons between before and after CPAP in each corresponding group.

P values represent comparisons with regards to the changes with CPAP treatment between overlap syndrome and pure COPD in each corresponding group.

IC inspiratory capacity.

Overall, the increase in walking distance (delta-distance) after CPAP treatment was significantly related to the attenuation of sleep apnoea/hypopnoea episodes (delta-AHI) (r = 0.564, P = 0.001) (Figure 2) and de-saturation episodes (delta-ODI) (r = 0.402, P = 0.007). In univariate analysis, only delta-AHI and delta-ODI were significantly correlated with delta-distance (Table E1). Although the sleep architectures (SWS and REM) were significant changed after CPAP treatment, there were no significant correlations between delta-distance and delta-REM as well as delta-distance and delta-SWS no matter they were represented in minutes or % of TST. Multivariate analysis revealed that delta-AHI was the only independent factor associated with delta-distance.
Figure 2

Correlation between the changes in apnoea-hypopnoea index (delta-AHI) and the changes in walking distance (delta-distance) with CPAP treatment in the patients with overlap syndrome.

In the patients with overlap syndrome, 14 (63.6%) received continuous CPAP treatment for three months. Of these patients, 10 patients had adequate CPAP compliance, which was defined as the use of CPAP > 4 hours per night and > 5 days per week. Eight (36.4%) patients refused continuous CPAP treatment. Three of these eight patients refused CPAP treatment because of the personal issues and the other five patients did not feel much better after two nights of CPAP treatment. The AHI after three months of follow up was not significantly different between the continuous CPAP and non-CPAP treatment groups (36.2 ± 19.1, n = 10 and 35.6 ± 14.2, n = 8, respectively). In addition, there was no significant change in pulmonary function in terms of FEV1 in either the continuous CPAP treatment group (53.9 ± 30.9% predicted, n = 10) or non-CPAP treatment group (47.4 ± 23.9% predicted, n = 8) when compared to the baseline values before treatment (52.7 ± 31.3% predicted, n = 10 and 46.1 ± 24.5% predicted, n = 8, respectively). The continuous CPAP treatment group maintained the increase in walking distance with CPAP treatment after three months of follow-up (57.0 ± 39.2 M) (Online supplement Figure 1). However, the walking distance returned to baseline in non-CPAP treatment group after three months of follow-up.

Discussion

This study demonstrated that two nights of nocturnal CPAP treatment was associated with an improvement in walking capacity in COPD patients with OSA. In addition, the increase in walking distance was clinically significant and relevant [24]. To date, this is the first study to report the impact of CPAP treatment on COPD patients with OSA.

Exercise performance is an important issue for COPD patients because it is associated with mortality, hospitalization, and acute exacerbation [26]. Poor exercise performance also leads to physical inactivity, and subsequently to muscle atrophy and de-conditioning, which causes a further decrease in exercise performance leading to a vicious cycle [4]. Many factors are associated with exercise performance including age, body weight, pulmonary function, oxygenation, dyspnoea sensation, skeletal muscles, cardiovascular disease, cognitive function, and obstructive sleep apnoea [7, 8, 25]. Patients with heart failure, renal insufficiency, neuromuscular disease, mood or sleep disorders other than OSA, and chronic respiratory failure were excluded from this study so as to focus on the effects of OSA on the walking capacity of COPD patients.

Hypoxemia, one of the cardinal features of OSA, is known to be more severe in overlap syndrome than in either individual syndrome, and this was also found in the current study. In an animal study, chronic intermittent hypoxemia was found to increase diaphragmatic and limb muscle fatigue in rats [26]. In humans, inspiratory muscle dysfunction has been noted in severe obstructive sleep apnoea [27]. This suggests that intermittent hypoxemia impairs muscle function including accessory muscles, diaphragm and limb muscles. Moreover, skeletal muscle atrophy and dysfunction, a common complication in COPD, contribute to increased nocturnal hypoxemia. The use of nocturnal CPAP to break up this vicious cycle may act by attenuating skeletal muscle dysfunction, which may in turn improve the walking capacity in patients with overlap syndrome.

Sleep deprivation has been documented to be associated with poor exercise performance [28]. In addition, poor exercise performance has also been reported in patients with OSA, which is characterised by sleep fragmentation, worsened sleep architecture, and subjective daytime sleepiness [29]. Similar results were also demonstrated in this study; however, there was no significant association between the increase in walking distance (delta-distance) after CPAP treatment and the improvement in sleep architecture. The existence of ß-errors is possible, and further large-scale studies are needed to validate our findings.

Autonomic dysfunction, another cardinal feature of OSA, can be reversed by CPAP, and is also noted during peak exercise in COPD patients [30, 31]. In this study, we found that the patients with overlap syndrome had higher LF, LF/HF ratio, urine norepinephrine and epinephrine levels compared to the COPD patients, suggesting that a higher sympathetic activity exists in patients with overlap syndrome. This autonomic dysfunction has a negative impact on the walking performance of COPD patients with OSA. Increased sympathetic drive leads to inadequate blood flow, local inflammation, and abnormal skeletal muscle metabolism, which worsen the walking capacity of COPD patients [32]. The autonomic dysfunction and urine catecholamine levels in the patients with overlap syndrome after CPAP treatment decreased to the same values as the baseline of the COPD patients, indicating that CPAP reversed the autonomic dysfunction mostly caused by OSA. The significant decrease in pre-exercise heart rate after CPAP treatment in the patients with overlap syndrome may also represent an improvement in autonomic dysfunction after CPAP treatment. However, the extent to which this autonomic dysfunction affected the exercise capacity of the overlap syndrome patients is unknown.

CPAP treatment has been reported to improve survival in patients with overlap syndrome [33], and in this study we found that CPAP treatment improved the walking capacity in the patients with overlap syndrome. Whether this improvement in exercise capacity can be translated into an improvement in the mortality rate as reported previously [5, 6, 34] warrants a prospective, multi-center study with a larger study population and a longer observation time.

For the issues about the imbalance of emphysema component between groups are needed to be further discussion. All patients enrolled into this study were arranged HRCT. The severity of emphysema was assessed by an independent radiologist who was blinded to this study according to the Goddard scoring system [35]. In addition, the percentage of emphysema predominant type in overlap syndrome group is 5/22 (22.7%) and that in COPD group is 63.6% (14/22) (P = 0.014). Therefore, the result of this study should be caution to apply to emphysema predominant type COPD with OSA. In emphysema predominant type COPD, the lung volume increases, which decreases the severity of obstructive sleep apnea as Heinzer RC et al. described [36]. In addition, snores is one of our inclusion criteria that maybe the reason why the percentage of emphysema predominant type is relative low in overlap syndrome group.

In conclusion, the presence of OSA in COPD patients affects sleep architecture, increases hypoxemia episodes during sleep and increases sympathetic drive on awakening that together worsen the exercise capacity. Nocturnal CPAP treatment attenuated OSA-related dysfunction and then significantly increased the exercise capacity in the patients with overlap syndrome. However, this study is an observational study with a small sample size. Therefore, a large-scale double-blinded randomised control trial is needed to draw a more definite conclusion.

Notes

Declarations

Acknowledgements

The authors wish to thank Miss Sheng Te-Fang, Miss Chen Li-Fei, and Miss Jao Wen-Ching for their invaluable work in the technical support for the incremental shuttle walking test.

Financial/nonfinancial disclosures

The authors have reported to Respiratory Research that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Authors’ Affiliations

(1)
Department of Thoracic Medicine, Chang Gung Memorial Hospital and Chang Gung University, School of Medicine
(2)
Division of Pulmonary, Department of Internal Medicine, Shuang Ho Hospital
(3)
School of Respiratory Therapy, College of Medicine, Taipei Medical University
(4)
Department of Chest Medicine, Buddhist Tzu Chi General Hospital, Taichung Branch
(5)
Department of Cardiology Medicine, Chang Gung Memorial Hospital and Chang Gung University, School of Medicine

References

  1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176 (6): 532-555. 10.1164/rccm.200703-456SO.PubMedView ArticleGoogle Scholar
  2. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R: Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005, 171 (9): 972-977. 10.1164/rccm.200407-855OC.PubMedView ArticleGoogle Scholar
  3. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R: Physical activity and hospitalization for exacerbation of COPD. Chest. 2006, 129 (3): 536-544. 10.1378/chest.129.3.536.PubMedView ArticleGoogle Scholar
  4. Cooper CB: The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006, 119 (10 Suppl 1): 21-31.PubMedView ArticleGoogle Scholar
  5. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, Magnussen H: Physical activity is the strongest predictor of all-cause mortality in patients with chronic obstructive pulmonary disease: a prospective cohort study. Chest. 2011, 140 (2): 331-342. 10.1378/chest.10-2521.PubMedView ArticleGoogle Scholar
  6. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM: Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006, 61 (9): 772-778. 10.1136/thx.2006.060145.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Wegner RE, Jorres RA, Kirsten DK, Magnussen H: Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J. 1994, 7 (4): 725-729. 10.1183/09031936.94.07040725.PubMedView ArticleGoogle Scholar
  8. Dam TT, Ewing S, Ancoli-Israel S, Ensrud K, Redline S, Stone K: Association between sleep and physical function in older men: the osteoporotic fractures in men sleep study. J Am Geriatr Soc. 2008, 56 (9): 1665-1673. 10.1111/j.1532-5415.2008.01846.x.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Leggett RJ, Flenley DC: Portable oxygen and exercise tolerance in patients with chronic hypoxic cor pulmonale. Br Med J. 1977, 2 (6079): 84-86. 10.1136/bmj.2.6079.84.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Davidson AC, Leach R, George RJ, Geddes DM: Supplemental oxygen and exercise ability in chronic obstructive airways disease. Thorax. 1988, 43 (12): 965-971. 10.1136/thx.43.12.965.PubMedPubMed CentralView ArticleGoogle Scholar
  11. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006, 174 (8): 867-874. 10.1164/rccm.200604-506OC.PubMedView ArticleGoogle Scholar
  12. Kent BD, McNicholas WT, Verbraecken J: Disturbed sleep and COPD outcomes: cart meets horse. Sleep Med. 2012, 13 (5): 453-454. 10.1016/j.sleep.2012.02.001.PubMedView ArticleGoogle Scholar
  13. Marklund M, Verbraecken J, Randerath W: Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy. Eur Respir J. 2012, 39 (5): 1241-1247. 10.1183/09031936.00144711.PubMedView ArticleGoogle Scholar
  14. Basner RC: Continuous positive airway pressure for obstructive sleep apnea. N Engl J Med. 2007, 356 (17): 1751-1758. 10.1056/NEJMct066953.PubMedView ArticleGoogle Scholar
  15. Kushida CA, Chediak A, Berry RB, Brown LK, Gozal D, Iber C, Parthasarathy S, Quan SF, Rowley JA: Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep Med. 2008, 4 (2): 157-171.PubMedGoogle Scholar
  16. EEG arousals: Scoring rules and examples: a preliminary report from the sleep disorders atlas task force of the american sleep disorders association. Sleep. 1992, 15 (2): 173-184.Google Scholar
  17. Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. the report of an american academy of sleep medicine task force. Sleep. 1999, 22 (5): 667-689.Google Scholar
  18. Rosano TG, Swift TA, Hayes LW: Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma. Clin Chem. 1991, 37 (10 Pt 2): 1854-1867.PubMedGoogle Scholar
  19. Rosano TG: Liquid-chromatographic evaluation of age-related changes in the urinary excretion of free catecholamines in pediatric patients. Clin Chem. 1984, 30 (2): 301-303.PubMedGoogle Scholar
  20. Liu WT, Wang CH, Lin HC, Lin SM, Lee KY, Lo YL, Hung SH, Chang YM, Chung KF, Kuo HP: Efficacy of a cell phone-based exercise programme for COPD. Eur Respir J. 2008, 32 (3): 651-659. 10.1183/09031936.00104407.PubMedView ArticleGoogle Scholar
  21. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE: Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992, 47 (12): 1019-1024. 10.1136/thx.47.12.1019.PubMedPubMed CentralView ArticleGoogle Scholar
  22. Weitzenblum E, Chaouat A, Kessler R, Canuet M, Hirschi S: The overlap syndrome: association of COPD and obstructive sleep apnoea. Rev Mal Respir. 2010, 27 (4): 329-340. 10.1016/j.rmr.2010.03.002.PubMedView ArticleGoogle Scholar
  23. Aihara K, Oga T, Harada Y, Chihara Y, Handa T, Tanizawa K, Watanabe K, Tsuboi T, Hitomi T, Mishima M, et al: Comparison of biomarkers of subclinical lung injury in obstructive sleep apnea. Respir Med. 2011, 105 (6): 939-945. 10.1016/j.rmed.2011.02.016.PubMedView ArticleGoogle Scholar
  24. Singh SJ, Jones PW, Evans R, Morgan MD: Minimum clinically important improvement for the incremental shuttle walking test. Thorax. 2008, 63 (9): 775-777. 10.1136/thx.2007.081208.PubMedView ArticleGoogle Scholar
  25. Prohaska TR, Eisenstein AR, Satariano WA, Hunter R, Bayles CM, Kurtovich E, Kealey M, Ivey SL: Walking and the preservation of cognitive function in older populations. Gerontologist. 2009, 49 (Suppl 1): S86-93.PubMedView ArticleGoogle Scholar
  26. McGuire M, MacDermott M, Bradford A: Effects of chronic intermittent asphyxia on rat diaphragm and limb muscle contractility. Chest. 2003, 123 (3): 875-881. 10.1378/chest.123.3.875.PubMedView ArticleGoogle Scholar
  27. Chien MY, Wu YT, Lee PL, Chang YJ, Yang PC: Inspiratory muscle dysfunction in patients with severe obstructive sleep apnoea. Eur Respir J. 2010, 35 (2): 373-380. 10.1183/09031936.00190208.PubMedView ArticleGoogle Scholar
  28. Mougin F, Simon-Rigaud ML, Davenne D, Renaud A, Garnier A, Kantelip JP, Magnin P: Effects of sleep disturbances on subsequent physical performance. Eur J Appl Physiol Occup Physiol. 1991, 63 (2): 77-82. 10.1007/BF00235173.PubMedView ArticleGoogle Scholar
  29. Lin CC, Hsieh WY, Chou CS, Liaw SF: Cardiopulmonary exercise testing in obstructive sleep apnea syndrome. Respir Physiol Neurobiol. 2006, 150 (1): 27-34. 10.1016/j.resp.2005.01.008.PubMedView ArticleGoogle Scholar
  30. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK: Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation. 1999, 100 (23): 2332-2335. 10.1161/01.CIR.100.23.2332.PubMedView ArticleGoogle Scholar
  31. Ketelaars CA, Schlösser MA, Mostert R, Huyer Abu-Saad H, Halfens RJ, Wouters EF: Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax. 1996, 51 (1): 39-43. 10.1136/thx.51.1.39.PubMedPubMed CentralView ArticleGoogle Scholar
  32. Middlekauff HR: Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail. 2010, 3 (4): 537-546. 10.1161/CIRCHEARTFAILURE.109.903773.PubMedPubMed CentralView ArticleGoogle Scholar
  33. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR: Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010, 182 (3): 325-331. 10.1164/rccm.200912-1869OC.PubMedView ArticleGoogle Scholar
  34. Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR: The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest. 2007, 132 (6): 1778-1785. 10.1378/chest.07-2050.PubMedView ArticleGoogle Scholar
  35. Goddard PR, Nicholson EM, Laszlo G, Watt I: Computed tomography in pulmonary emphysema. Clin Radiol. 1982, 33 (4): 379-387. 10.1016/S0009-9260(82)80301-2.PubMedView ArticleGoogle Scholar
  36. Heinzer RC, Stanchina ML, Malhotra A, Jordan AS, Patel SR, Lo YL, Wellman A, Schory K, Dover L, White DP: Effect of increased lung volume on sleep disordered breathing in patients with sleep apnoea. Thorax. 2006, 61 (5): 435-439. 10.1136/thx.2005.052084.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© Wang et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.